Study Evaluating Refacto For Pharmacovigilance

Hemophilia A Clinical Trial

Official title:

Pharmacovigilance Evaluation Of Refacto In Usual Care Settings

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00195442
• Other study ID #: 3082A-100690
• Status: Completed
• Phase: N/A
• First received: September 13, 2005
• Last updated: February 7, 2011
• Start date: July 1999
• Est. completion date: January 2010

Study information

• Verified date: February 2011
• Source: Wyeth is now a wholly owned subsidiary of Pfizer
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Paul-Ehrlich-Institut
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to investigate the effectiveness and safety of treatment with ReFacto under conditions of routine therapy. Furthermore a continuous benefit/risk assessment will be done.

Description:

Non-interventional study: subjects to be selected according to the usual clinical practice of their physician

Recruitment information / eligibility

• Status: Completed
• Enrollment: 288
• Est. completion date: January 2010
• Est. primary completion date: January 2010
• Accepts healthy volunteers: No
• Gender: Male
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Proven diagnosis of Hemophilia A

Exclusion Criteria:

• Contraindications according to Summary of Product Characteristics

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Hemophilia A

Intervention

Drug:
• Moroctocog alfa
Patients will be treated in accordance with the requirements of the labeling of ReFacto (Moroctocog alfa) in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.

Locations

Country	Name	City	State
Austria	Pfizer Investigational Site	Vienna
Germany	Pfizer Investigational Site	Berlin
Germany	Pfizer Investigational Site	Berlin
Germany	Pfizer Investigational Site	Bermen
Germany	Pfizer Investigational Site	Bonn	Nordrhein-Westfalen
Germany	Pfizer Investigational Site	Erlangen
Germany	Pfizer Investigational Site	Frankfurt	Hessen
Germany	Pfizer Investigational Site	Frankfurt a. M.
Germany	Pfizer Investigational Site	Giessen	Hessen
Germany	Pfizer Investigational Site	Halle	Sachsen-Anhalt
Germany	Pfizer Investigational Site	Hamburg
Germany	Pfizer Investigational Site	Hannover	Niedersachsen
Germany	Pfizer Investigational Site	Heidelberg
Germany	Pfizer Investigational Site	Homburg
Germany	Pfizer Investigational Site	Klipphausen
Germany	Pfizer Investigational Site	Leipzig
Germany	Pfizer Investigational Site	Lubeck
Germany	Pfizer Investigational Site	Muenchen
Germany	Pfizer Investigational Site	Muenchen
Germany	Pfizer Investigational Site	Muenster
Germany	Pfizer Investigational Site	Potsdam
Germany	Pfizer Investigational Site	Rostock	Mecklenburg-Vorpommern
Germany	Pfizer Investigational Site	Schwerin
Germany	Pfizer Investigational Site	Stadtroda	Thuringen
Germany	Pfizer Investigational Site	Ulm
Germany	Pfizer Investigational Site	Wiesbaden

Sponsors (1)

Lead Sponsor	Collaborator
Wyeth is now a wholly owned subsidiary of Pfizer

Countries where clinical trial is conducted

Austria,  Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean Number of Bleeding Episodes Per Patient Year	Participants with hemophilia A suffer from a hereditary lack of blood clotting factor VIII. As a consequence, the ability of the blood to coagulate is reduced and bleedings at any site or organ of the body may occur after minor injury or even spontaneously. Predominantly, joints, muscles, and internal organs are affected by bleeding complications. Participants reported the occurrence of each bleeding episode while on study. The bleeding rate for each participant was calculated by number of reported episodes per years on study.	Baseline up to a mean duration of 54 months	No
Primary	Mean Number of Bleeding-related Exposure Days Per Patient Year	Exposure days are the number of days of treatment with ReFacto.	Baseline up to a mean duration of 54 months	No
Primary	Mean Number of Exposure Days Per Patient Year	Exposure days are the number of days of treatment with ReFacto.	Baseline up to a mean duration of 54 months	No
Secondary	Number of Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)	AEs are any undesired side effect which occurred in a participant undergoing study treatment independent of whether a correlation with study treatment was suspected or not. SAEs are undesired events which were lethal or life-threatening, made hospitalization or extension of hospital stay necessary, lead to permanent damage with handicap (inability to work), as well as congenital anomalies, malignant disease, or overdosing. Also presence of inhibitors, thrombotic events, erythrocyte agglutination, allergic reactions, less than therapeutic effect, and inhibitor development were considered SAEs.	Baseline up to a mean duration of 54 months	Yes
Secondary	Number of Participants With de Novo Inhibitor Formation	The applied criteria of clinical relevance for de novo inhibitor formation was defined as normal Factor VIII dosage was ineffective to control a bleeding, control of bleeding episodes required increasing Factor VIII dosage, change of concentrate type (administration of activated Prothrombin-Complex Concentrate [aPCC] or recombinant Factor VII [rFVII ]) was needed to stop a bleeding, or change of therapy strategy (intensive prophylaxis or Immune Tolerance Induction [ITI]) was required.	Baseline up to a mean duration of 54 months	Yes
Secondary	Mean Annual ReFacto Consumption Per Patient Year	ReFacto administered as International Units (IU) according to the physician's decision following the drug's summary of product characteristics (SPC) and according to usual care principles.	Baseline up to a mean duration of 54 months	No
Secondary	Number of Participants for Physicians' Assessment of Satisfaction With Treatment Success	Subjective assessment by the physician to evaluate treatment success (i.e., control of bleeding, Factor VIII consumption, treatment efficacy and tolerance, handling of preparation, and days missing from work or school). Physician rated assessment could be categorized as Very satisfied, Satisfied, Unsatisfied, or Very unsatisfied; no criteria was pre-specified for the assessment categories in this observational study.	Baseline up to a mean duration of 54 months	No
Secondary	Number of Participants for Physicians' Assessment of Efficacy	Subjective assessment by the physician to evaluate control of bleeding. Physician rated assessment could be categorized as Very good, Good, Moderate, or Poor; no criteria was pre-specified for the assessment categories in this observational study.	Baseline up to a mean duration of 54 months	No
Secondary	Number of Participants for Patients' Assessment of Efficacy	Subjective assessment by the participant to evaluate control of bleeding. Patient rated assessment could be categorized as Very good, Good, Moderate, Poor, or No specification; no criteria was pre-specified for the assessment categories in this observational study.	Baseline up to a mean duration of 54 months	No
Secondary	Number of Participants for Physicians' Assessment of Tolerance	Subjective assessment by the physician to evaluate the participants' tolerance of treatment with ReFacto (i.e., dose, administration method, or adverse effects). Physician rated assessment could be categorized as Very good, Good, Moderate, or Poor; no criteria was pre-specified for the assessment categories in this observational study.	Baseline up to a mean duration of 54 months	No
Secondary	Number of Participants for Patients' Assessment of Tolerance	Subjective assessment by the participant to evaluate tolerance of treatment with ReFacto (i.e., dose, administration method, or adverse effects). Patient rated assessment could be categorized as Very good, Good, Moderate, Poor, or No specification; no criteria was pre-specified for the assessment categories in this observational study.	Baseline up to a mean duration of 54 months	No
Secondary	Number of Participants for Physicians' Assessment of Handling of ReFacto	Subjective assessment by the physician to evaluate the participants' handling (preparation and administration) of ReFacto. Physician rated assessment could be categorized as Very good, Good, Moderate, or Poor; no criteria was pre-specified for the assessment categories in this observational study.	Baseline up to a mean duration of 54 months	No
Secondary	Number of Participants for Patients' Assessment of Handling of ReFacto	Subjective assessment by the participant on handling (preparation and administration) of ReFacto. Patient rated assessment could be categorized as Very good, Good, Moderate, Poor, or No specification; no criteria was pre-specified for the assessment categories in this observational study.	Baseline up to a mean duration of 54 months	No
Secondary	Number of Participants for Days of Sick Leave Per Month	Days of sick leave (missing work or school) per month categorized as No days of absence, Number of days of absence, Long-term inability to work or study, Not employed or at school, or No specification.	Baseline up to a mean duration of 54 months	No

External Links

•   To obtain contact information for a study center near you, click here.